Industry News
Study suggests drug may reverse psychosis
Cannabis, a drug believed to increase the risk of psychosis in users, contains a compound that may be able to reverse psychotic behaviour, Monash researchers have found.
[ + ]Benitec tells AGM of better times ahead
"Seeing you all here means the company has survived," the chairman of RNAi specialist Benitec (ASX:BLT) Ray Whitten, told shareholders at today's AGM in Sydney. [ + ]
In brief: C3, SSH, Axon
Clinical Cell Culture's (ASX:CCE) co-founder Prof Fiona Wood will step down from the company's board on December 31. She will remain as a consultant, an R&D partner through her research vehicle the McComb Foundation, and a substantial shareholder. [ + ]
Visiomed aims to raise $1.6m
Perth-based biomedical devices developer Visiomed Group (ASX:VSG) is aiming to raise AUD$1.6 million after costs through a placement of up to 90 million shares at $0.02 each. [ + ]
Ambri on the hunt for M&A targets
Sydney-based Ambri (ASX:ABI) is looking to merge with another medical diagnostics company with products that are closer to market. [ + ]
Biomedical facility opens in WA
A biomedical research facility tipped to speed up research into the genetic causes of human diseases has been officially opened.
[ + ]Select Vaccines to raise $1.79m
Melbourne's Select Vaccines (ASX:SLT) is planning to raise AUD$1.79 million through a rights issue and placement to provide working capital for the development of a vaccine against hepatitis C and further development of diagnostic assays. [ + ]
US$1m milestone payment for BioDiem
Melbourne-based flu vaccine company BioDiem (ASX:BDM) has received a payment of US$1 million (AUD$1.35 million) from Akzo Nobel's Nobilon, bringing its total milestone payments to US$3 million. [ + ]
Unknown party lists Psiron on Berlin-Bremen stock exchange
The Berlin-Bremen stock exchange in Germany has advised Psiron (ASX:PSX) that a third party has applied for the Sydney-based oncology therapy developer's shares to be listed on Freiverkehr, the stock exchange's third market segment. [ + ]
Virax aims to raise $3.85m after NIH disappointment
Melbourne immunotherapy developer Virax Holdings (ASX:VHL) has lodged a prospectus to raise AUD$3.85 million through a rights issue for the further development of its HIV therapeutic vaccine VIR201 following its unsuccessful bid for US NIH funding. [ + ]
Epitan CEO replaced, appoints CSO
Melbourne-based Epitan's (ASX:EPT, ADR:EPTNY, XETRA:UR9) CEO Iain Kirkwood has been replaced by Dr Philippe Wolgen, effective immediately. [ + ]
Cambridge research delves into memory
Animals as diverse as sea slugs, fruit flies, mice and humans can learn. But how memories are stored in the brain and then retrieved is still a mystery, and Australian researcher Prof Seth Grant is trying to solve it. [ + ]
Positive results for Peplin phase IIa 'sun spot' trial
Peplin (ASX:PEP) has reported positive results from its phase IIa clinical trial of its proprietary drug PEP005 Topical in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer. [ + ]
New professor of chemistry
A world leader in the application of nuclear magnetic resonance (NMR) spectroscopy, Robert Brownlee, has been appointed Professor of Chemistry at La Trobe University.
[ + ]APIA to broadcast live heart disease cases
Cardiologists and medical professionals will witness the biggest heart disease live case demonstration in Australian history at the inaugural Asia-Pacific Interventional Advances Conference (APIA), taking place 29 November to 2 December in Newcastle. [ + ]
